Pular para o conteúdo principal
Ranking Invest

SYRE - Spyre Therapeutics, Inc.

Segmento: HealthcareSpyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Análise Ranking Invest

Valuation estimado
$ 347.30 Mi
Valor de Mercado
$ 7.99 Bi
Sobrepreço (AV)+2199.9%
IVR
0.04A companhia vale 0,04 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.10O valuation alternativo equivale a -10% do valor de mercado da companhia.
MLL
-0.10O lucro líquido dos controladores em 16 trimestres equivale a -10% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 1.10 Bi

Dívida Líquida

-$ 162.01 Mi

L4T

-$ 178.92 Mi

Indicadores Básicos

ROE

-16.25%

Índices de Previsibilidade

Receita Líquida

G0.97

Lucro

C0.34

Margem

D0.85

Índices de Tendência

Receita Líquida

E-6.63

Lucro

F-4.98

Margem

A9.53

Índices de Endividamento

DIV/PAT

-0.15

DIV/L4T

0.91

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.